STAT+: Pharmalittle: We’re Reading About a Trump Deal with Regeneron, Reclassifying Medical Marijuana, and More

Why It Matters

The deal could curb Medicaid drug spend while boosting biotech investment, and the cannabis reclassification opens new market and research avenues, reshaping industry economics.

Key Takeaways

• Regeneron to cut Medicaid drug prices, including $225 Praluent.
• Company pledges $27 billion U.S. drug‑development investment.
• FDA approves Otarmeni, first gene therapy via National Priority Voucher.
• White House reclassifies medical marijuana to Schedule III, easing regulation.
• Reclassification grants tax breaks and expands cannabis research opportunities.

Pulse Analysis

The Trump‑Regeneron agreement arrives after a year of aggressive pressure on the nation’s largest drug makers to lower prices for Medicaid. By securing a $225 price for Praluent and broader discounts, the administration aims to reduce federal healthcare outlays, while Regeneron’s $27 billion investment promises to keep research and manufacturing jobs stateside, reinforcing the United States’ position in the global biotech race.

Otarmeni’s approval under the National Priority Voucher (NPV) program signals a new pathway for high‑cost, high‑impact therapies to reach the market faster. The NPV, designed to accelerate development of breakthrough treatments, grants a fast‑track review that can shave years off the regulatory timeline. For investors and patients alike, this represents a tangible incentive to fund innovative gene‑editing projects, potentially reshaping the therapeutic landscape for rare diseases.

Reclassifying medical marijuana to Schedule III is a watershed moment for the cannabis sector. The change removes the most restrictive scheduling, offering a 25 percent tax deduction on production costs and simplifying clinical trial approvals. Companies can now pursue research with fewer regulatory hurdles, likely spurring a wave of new products and attracting capital. Politically, the move underscores a broader GOP shift toward pragmatic drug policy, balancing law‑enforcement concerns with economic opportunities in a rapidly expanding market.